Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Original statement
لكن التكميم ده بيموت منه بقى اصلا فانت خليت السرطان ده لما يجي عند سن 550 سنه جه عند سن 55 سنه
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr.D Clinics - Diaa Al Awady is live!التكميم (Open source)
- Published
- 6 May 2025
- Timestamp
- 1:22:42 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available. The surrounding passage uses figurative ages (600, 550 years) in his theory of cancer as a 'defence plan'.
- Claimed mechanism
Tissue damage from disturbed digestion accelerates cancer as a 'defence plan'.
- Claimed health effect
Earlier cancer.
- Population concerned
Sleeve patients
- Geographic restriction by Elawady
none found
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: low – Further research is likely to change the assessment considerably.
1. What was claimed?
That sleeve brings cancer forward.
2. What is demonstrably correct?
Long-term reflux and Barrett's after sleeve are documented (C-BAR-04), so a site-specific oesophageal risk is biologically plausible but unproven.
3. What is wrong or exaggerated?
Overall cancer mortality was lower, not higher, after bariatric surgery: SOS cancer death HR 0.77 (A-BAR-05), Adams 60% lower cancer mortality (A-BAR-03), SOS 2007 cancer deaths 29 vs 47 (A-BAR-02).
4. What remains unclear?
Sleeve-specific long-term cancer data are limited.
5. Which studies support it?
None directly.
6. Which studies contradict it?
7. What applies to Germany and Europe?
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. What is known about Egypt?
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. What practical conclusion is appropriate?
There is no evidence that sleeve generally causes earlier cancer; reflux-related oesophageal risk should be monitored.
Assessment details
- Rationale for certainty of evidence
Cancer mortality is lower after bariatric surgery in cohorts (SOS HR 0.77; Adams -60%), but data are observational and mostly from older procedures; sleeve-specific oesophageal cancer risk is not settled.
- Source quality
Theory-based statement; no data cited.
- Regional transferability
Applicable.
- Individual exceptions
Possible procedure-specific risks (e.g., oesophageal adenocarcinoma after long-term reflux) are not yet quantified.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Elawady claimed that sleeve gastrectomy makes cancer appear much earlier. Long-term studies found the opposite for cancer overall: fewer cancer deaths after weight-loss surgery than in similar people without surgery. Whether long-term reflux after sleeve raises the risk of cancer of the gullet is still unknown.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (3)
-
Swedish study: fewer deaths after weight-loss surgery
Sjöström L et al.. N Engl J Med 2007 · PMID 17715408 · DOI 10.1056/NEJMoa066254Cohort studycited by the Tayebat archiveabstract only checkedOver about 11 years, people who had surgery had roughly 24-29% lower risk of dying than matched controls.
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test mortality effect
- How was the study done?
Prospective matched study
- How many people, animals or samples were studied?
4047 adults
- What was actually found?
Fewer deaths after surgery
- How large was the observed effect?
Adjusted HR 0.71
- What do the results mean in everyday life?
Surgery was linked to living longer
- What are the study's limitations?
Not randomized; older techniques
- What does it say about Elawady's specific claim?
Argues against 'surgery kills'
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Exact causal size
-
Gastric bypass: fewer deaths overall, but more accident and suicide deaths
Adams TD et al.. N Engl J Med 2007 · PMID 17715409 · DOI 10.1056/NEJMoa066603Cohort studycited by the Tayebat archiveabstract only checked★ key studyTotal deaths were 40% lower after surgery, while deaths from accidents and suicide were higher (11.1 vs 6.4 per 10,000 person-years).
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Long-term mortality
- How was the study done?
Matched retrospective cohort
- How many people, animals or samples were studied?
15,850 people
- What was actually found?
Total deaths down, external-cause deaths up
- How large was the observed effect?
37.6 vs 57.1 total; 11.1 vs 6.4 non-disease per 10,000 PY
- What do the results mean in everyday life?
Net survival benefit with a specific mental health and accident risk
- What are the study's limitations?
Observational
- What does it say about Elawady's specific claim?
Supports self-harm concern, contradicts 'lethal'
- Do the results apply to Germany and Europe?
Comparable to Nordic findings
- What can explicitly not be concluded from this study?
Causation of suicide excess
-
Swedish 24-year study: surgery added about 3 years of life
Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449Cohort studycited by the Tayebat archivefull text checked★ key studyOperated patients lived about 3 years longer than non-operated patients with obesity, but still about 5.5 years less than the general population (non-operated: about 8.5 years less).
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Life expectancy
- How was the study done?
Prospective controlled cohort with population reference
- How many people, animals or samples were studied?
5182 people
- What was actually found?
Surgery gained 3 years; gap to population 5.5 vs 8.5 years
- How large was the observed effect?
HR death 0.77; +3.0 years
- What do the results mean in everyday life?
Surgery reduced but did not remove the life-expectancy loss linked to severe obesity
- What are the study's limitations?
Not randomized; old operations
- What does it say about Elawady's specific claim?
Number correct, implication 'surgery shortens life' wrong
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
That surgery causes the remaining 5.5-year gap
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Meta-analysis: Barrett's after sleeve
Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041Meta-analysisindependent cross-checkabstract only checked★ key studyAbout 5.6% developed new Barrett's esophagus; reflux and acid-medication use were about 3 times more frequent after sleeve.
Sleeve gastrectomy makes cancer appear decades earlier (it 'kills' and brings cancer forward).
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
BE after SG
- How was the study done?
Meta-analysis
- How many people, animals or samples were studied?
2046
- What was actually found?
BE 5.6%; GERD x3
- How large was the observed effect?
RR GERD 3.32
- What do the results mean in everyday life?
Reflux is a major downside of sleeve
- What are the study's limitations?
Heterogeneous observational
- What does it say about Elawady's specific claim?
Supports reflux/BE claim, not 'inevitable'
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Cancer risk
No study in this group is marked as key.
Regional context
Germany / EU
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
Egypt
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
What applies in my country?
General scientific assessment
Mostly false Not supported: overall cancer deaths were lower after bariatric surgery.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Effects of bariatric surgery on mortality in Swedish obese subjects.. Sjöström L et al.. N Engl J Med 2007 · PMID 17715408 · DOI 10.1056/NEJMoa066254
- Long-term mortality after gastric bypass surgery.. Adams TD et al.. N Engl J Med 2007 · PMID 17715409 · DOI 10.1056/NEJMoa066603
- Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study.. Carlsson LMS et al.. N Engl J Med 2020 · PMID 33053284 · DOI 10.1056/NEJMoa2002449
- Risk of De Novo Barrett's Esophagus Post Sleeve Gastrectomy: A Systematic Review and Meta-Analysis of Studies With Long-Term Follow-Up.. Chandan S et al.. Clin Gastroenterol Hepatol 2025 · PMID 39059544 · DOI 10.1016/j.cgh.2024.06.041